At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
LEO 80190 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Calcipotriol Plus Hydrocortisone in Paediatric Patients (Aged 6 to 17 Years) With Psoriasis Vulgaris on the Face and on the Intertriginous Areas
In Brief
A Phase 3 clinical trial evaluating LEO 80190 and Hydrocortisone for Psoriasis Vulgaris. Completed, enrolled 40 participants across 1 site.
Detailed Summary
An international, multi-centre, prospective, randomised, double-blind, active-controlled, 2-arm, parallel group, 8-week, phase 3 clinical study in paediatric patients (aged 6 to 17 years) with psoriasis vulgaris on the face and on the intertriginous areas
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesFrance
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedNov 2009
Primary CompletionJun 2010
Study CompletionDec 2010
TodayJul 2026
First PostedNov 4, 2009
Enrollment StartOct 1, 2009
Primary CompletionJun 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.7 years ago
Interventions
LEO 80190drug
Applied once daily
Hydrocortisonedrug
Applied once daily